Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
HCM
HCM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HCM News
HUTCHMED Receives Conditional Approval for ORPATHYS® in Gastric Cancer
6d ago
Newsfilter
HUTCHMED to Announce Interim Results on July 30
Jun 30 2026
Newsfilter
HUTCHMED's Fanregratinib Meets Primary Endpoint in Phase 2 Study
Jun 25 2026
NASDAQ.COM
Fanregratinib Shows Promising Results in ICC Treatment
Jun 25 2026
Newsfilter
HUTCHMED Reports Phase III Results for Sovleplenib in wAIHA
Jun 12 2026
NASDAQ.COM
Sovleplenib Shows Promising Results in wAIHA Treatment
Jun 12 2026
Newsfilter
HUTCHMED to Present New Data at ASCO Meeting
May 22 2026
Newsfilter
HUTCHMED and Innovent's Drug Combination Approved in China
May 21 2026
NASDAQ.COM
HUTCHMED and Innovent Jointly Approved New Drug
May 21 2026
Newsfilter
Virtual Investor Conference Presentations Now Available Online
Apr 29 2026
Globenewswire
Deutsche Bank to Host Depositary Receipts Investor Conference
Apr 23 2026
Globenewswire
HUTCHMED to Present New Data on HMPL-A580 at AACR 2026
Apr 09 2026
Newsfilter
HUTCHMED Initiates Phase III Trial for HMPL-760
Mar 23 2026
NASDAQ.COM
HUTCHMED Announces Withdrawal of TAZVERIK® from Chinese Market
Mar 09 2026
Newsfilter
HUTCHMED Board Member Changes Announced
Mar 06 2026
Newsfilter
HUTCHMED Reports $457 Million Net Income for 2025 Amid Strategic Growth
Mar 05 2026
Newsfilter
Show More News
